Pamela Trillo Aliaga

Dr. Pamela Trillo Aliaga

Thoracic Oncology, European Institute of Oncology, Milan, Lombardy, Italy
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 January 2022 in European Journal of Cancer
Verified
Journal Article
Closed access
PTPaolo Tarantino
Paolo Tarantino
Sara GandiniSara Gandini
Sara Gandini
ENEleonora Nicolò
Eleonora Nicolò
PAPamela Trillo Aliaga
Pamela Trillo Aliaga
FGFederica Giugliano
Federica Giugliano
GCGiuseppe Curigliano
Giuseppe Curigliano

20 October 2023 in Cancers
Verified
Journal Article
Open access
PDF file
IAIlaria Attili
Ilaria Attili
CCCarla Corvaja
Carla Corvaja
GSGianluca Spitaleri
Gianluca Spitaleri
ESEster Del Signore
Ester Del Signore
PAPamela Trillo Aliaga
Pamela Trillo Aliaga
FMFilippo de Marinis
Filippo de Marinis
Tyrosine kinase inhibitors (TKIs) revolutionized the treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC) harboring most driver gene alterations. Starting from the first generation, research rapidly moved to the development of newer, more selective generations of TKIs, obtaining improved results in terms of disease control and survival. However, the use of novel generations of TKIs is not without limitations. We reviewed the main results obtained, as well as the ongoing clinical trials with TKIs in oncogene-addicted NSCLC, together with the biology underlying their potential strengths and limitations. Across driver gene alterations, novel generations of TKIs allowed delayed resistance, prolonged survival, and improved brain penetration compared to previous generations, although with different toxicity profiles, that generally moved their use from further lines to the front-line treatment. However, the anticipated positioning of novel generation TKIs leads to abolishing the possibility of TKI treatment sequencing and any role of previous generations. In addition, under the selective pressure of such more potent drugs, resistant clones emerge harboring more complex and hard-to-target resistance mechanisms. Deeper knowledge of tumor biology and drug properties will help identify new strategies, including combinatorial treatments, to continue improving results in patients with oncogene-addicted NSCLC.

19 July 2023 in Cancer Treatment Reviews
Verified
Journal Article
Closed access
IAIlaria Attili
Ilaria Attili
APANTONIO PASSARO
ANTONIO PASSARO
CCCarla Corvaja
Carla Corvaja
PAPamela Trillo Aliaga
Pamela Trillo Aliaga
ESEster Del Signore
Ester Del Signore
FMFilippo de Marinis
Filippo de Marinis

28 September 2023 in Cancers
Verified
Journal Article
Open access
PDF file
GSGianluca Spitaleri
Gianluca Spitaleri
PAPamela Trillo Aliaga
Pamela Trillo Aliaga
IAIlaria Attili
Ilaria Attili
ESEster Del Signore
Ester Del Signore
CCCarla Corvaja
Carla Corvaja
FMFilippo de Marinis
Filippo de Marinis
Non-Small-Cell Lung Cancer (NSCLC) can harbour different MET alterations, such as MET overexpression (MET OE), MET gene amplification (MET AMP), or MET gene mutations. Retrospective studies of surgical series of patients with MET-dysregulated NSCLC have shown worse clinical outcomes irrespective of the type of specific MET gene alteration. On the other hand, earlier attempts failed to identify the ‘druggable’ molecular gene driver until the discovery of MET exon 14 skipping mutations (METex14). METex14 are rare and amount to around 3% of all NSCLCs. Patients with METex14 NSCLC attain modest results when they are treated with immune checkpoint inhibitors (ICIs). New selective MET inhibitors (MET-Is) showed a long-lasting clinical benefit in patients with METex14 NSCLC and modest activity in patients with MET AMP NSCLC. Ongoing clinical trials are investigating new small molecule tyrosine kinase inhibitors, bispecific antibodies, or antibodies drug conjugate (ADCs). This review focuses on the prognostic role of MET, the summary of pivotal clinical trials of selective MET-Is with a focus on resistance mechanisms. The last section is addressed to future developments and challenges.

18 June 2025 in Molecules
Verified
Journal Article
Open access
PDF file
PAPamela Trillo Aliaga
Pamela Trillo Aliaga
GSGianluca Spitaleri
Gianluca Spitaleri
IAIlaria Attili
Ilaria Attili
CCCarla Corvaja
Carla Corvaja
EBElena Battaiotto
Elena Battaiotto
FMFilippo de Marinis
Filippo de Marinis
Non-small-cell lung cancer (NSCLC) can harbour different HER2 alterations: HER2 protein overexpression (2–35%), HER2 gene amplification (2–20%), and gene mutations (1–4%). The discovery of the HER2 gene in the 1980s raised great expectations for the treatment of several tumours. However, it was only in 2004 that HER2 mutations were identified, and they currently represent a key druggable target in NSCLC. Despite numerous strengths, there is only one FDA/EMA-approved targeted therapy, an antibody-drug conjugate (ADC) called trastuzumab deruxtecan for pretreated patients with HER2 mutant NSCLC. In the first-line treatment, the standard of care (SoC) remains chemotherapy with or without immunotherapy. In the past, pan-HER tyrosine kinase inhibitors (TKIs) were extensively studied with poor results. But, two newly developed HER2-specific TKIs with low EGFR WT inhibition (BAY2927088 and zongertinib) reported encouraging results and received the breakthrough therapy designation from the FDA. Ongoing clinical trials are investigating new agents. This review focuses on HER2 alterations. Additionally, the anti-HER2 therapies explored so far will be discussed in detail, including the following: HER2 inhibitors (pan-inhibitors and selective inhibitors), monoclonal antibodies (mAbs), and ADCs. A section of this paper is dedicated to the role of immunotherapy in HER2-altered NSCLC. The last section of this paper focuses on the drugs under development and their challenges.

19 July 2024 in Cancers
Verified
Journal Article
Open access
PDF file
IAIlaria Attili
Ilaria Attili
CCCarla Corvaja
Carla Corvaja
GSGianluca Spitaleri
Gianluca Spitaleri
PAPamela Trillo Aliaga
Pamela Trillo Aliaga
ESEster Del Signore
Ester Del Signore
FMFilippo de Marinis
Filippo de Marinis
Background: Platinum-based chemotherapy is the current standard treatment option in patients with EGFR-mutant non-small-cell lung cancer (NSCLC) who progress on osimertinib. However, outcomes with chemotherapy are dismal, and the treatment of central nervous system (CNS) disease is an unmet need in this setting. Methods: Patients with EGFR-mutant NSCLC who were candidates to receive osimertinib in the metastatic setting at our Center from 2015 to 2022 were retrospectively evaluated to identify patients who received standard platinum-based chemotherapy post-osimertinib. Data were collected on treatment outcomes, with a focus on brain metastases and progression patterns. Results: A total of 220 patients received indication for osimertinib in the study period; n = 176 had adequate follow-up data. Overall, n = 117 patients experienced disease progression on osimertinib. The median time to osimertinib progressive disease (PD) was 15 months (95% confidence interval CI 13–18). Of them, 51 patients (45%) had no access to further treatments. Of the remaining patients, n = 8 received experimental treatments, and n = 55 received standard platinum-based chemotherapy and were considered for this study. Median duration of chemotherapy was 3 months (95% CI 2–5); the best responses among 53 evaluable patients were observed as follows: 15% partial response/complete response (PR/CR), 40% stable disease (SD), 45% PD. Median progression-free survival (PFS) and overall survival (OS) were 3 (95% CI 2–5) and 10 (95% CI 6–15) months, respectively. All patients had baseline and follow-up brain radiologic assessments, and n = 23 had brain metastases at the start of chemotherapy. With a median follow-up of 13 months, intracranial PD occurred in 47% patients, being the first site of PD in 59% of cases. The median time for intracranial (IC) PD was 2 months (95% CI 2–7). IC PD occurred as oligometastatic in 29%, whereas in 71% of cases, it was associated with systemic PD. Conclusions: Access to subsequent treatments and CNS progression are confirmed unmet needs in EGFR-mutant NSCLC patients. Clinical and CNS-specific outcomes in patients receiving standard chemotherapy after the failure of osimertinib are dismal. Novel upfront treatment options with demonstrated prolonged PFS and better CNS outcomes may help address this important issue.